Skip to main content
. Author manuscript; available in PMC: 2022 Apr 21.
Published in final edited form as: J Gastrointest Surg. 2019 Jul 16;24(8):1729–1735. doi: 10.1007/s11605-019-04320-y

Table 2:

Staging and Pathologic Outcomes for Cancer Patients

n=121

Pretherapy clinical stage
I 20 (16.5)
II 19 (15.7)
III 52 (42.0)
IVA 9 (7.4)
Unknown 21 (17.4)
Diagnosis
Adenocarcinoma 114 (94.2)
Squamous cell carcinoma 6 (5.0)
Adenosquamous carcinoma 1 (0.8)
Neoadjuvant Therapy
Chemoradiation 80 (66.1)
Chemotherapy 7 (5.8)
None 31 (25.6)
Other/Unknown 3 (2.5)
Pathology
 T stage
T0 18(14.9)
Tis 3(2.5)
T1 38(31.4)
T2 17 (14.0)
T3 44 (36.4)
T4 0
Unknown 1 (0.8)
N stage
N0 81(66.1)
N1 25(21.4)
N2 10(6.3)
N3 2(0.9)
Unknown 3 (2.7)
Number of nodes retrieved 15.5 [12.0,22.0]
Margin negative 99/105 (94.3)
Treatment effect grade n=63
0 (complete) 12 (19.0)
1 (moderate) 17 (27.0)
2 (minimal) 26 (41.3)
3 (poor) 4 (6.3)
Response not graded 4 (6.3)

Reported as number (percent) or median [IQR]. If data were not available for the entire cohort, reported as number/total (percent).